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7 Abstract
8 Many human glandular cancers metastasize along nerve tracts,
9 but the mechanisms involved are generally poorly understood.
10 The calcium-binding protein S100A4 is expressed at elevated
11 levels in human cancers where it has been linked to increased
12 invasion and metastasis. Here we report genetic studies in a
13 Drosophilamodel todeﬁne S100A4 effector functions thatmediate
14 metastatic dissemination of mutant Ras-induced tumors in
15 the developing nervous system. In ﬂies overexpressing mutant
16 RasVal12 and S100A4, there was a signiﬁcant increase in activation
17 of the stress kinase JNK and production of the matrix metallo-
18 proteinase MMP1. Genetic or chemical blockades of JNK and
19 MMP1 suppressed metastatic dissemination associated with
21S100A4 elevation, deﬁning required signaling pathway(s) for
22S100A4 in this setting. In clinical specimens of human breast
23cancer, elevated levels of themammalian paralogsMMP2,MMP9,
24and MMP13 are associated with a 4- to 9-fold relative decrease in
25patient survival. In individual tumors, levels of MMP2 and
26MMP13 correlated more closely with levels of S100A4, whereas
27MMP9 levels correlated more closely with the S100 family
28member S100P. Overall, our results suggest the existence of
29evolutionarily conserved pathways used by S100A4 to promote
30metastatic dissemination, with potential prognostic and thera-
31peutic implications for metastasis by cancers that preferentially
32exploit nerve tract migration routes. Cancer Res; 1–12. 2016 AACR.
33
34 Introduction
35 Certain tumor cells have a propensity to invade theneighboring
36 tissue and eventually establish new secondary tumors or metas-
37 tases while others cannot (1, 2). These results suggest that a
38 speciﬁc set of genes, different from those involved in the produc-
39 tion of the neoplasia, are involved in promoting a complex series
40 of steps to form metastases (3). The protein products of such
41 genes have been termedmetastasis-inducing proteins (MIP). One
42 such gene/protein is S100A4 (4), a member of the S100-calcium-
43 binding protein family (5). Although S100A4 cannot promote
44 tumor formation directly, it can stimulate the remaining steps in
45 the metastatic cascade in model rodent systems by combining
46 with oncogenes such as RasVal12 and neu (4, 6). Moreover, S100A4
47 is overexpressed in human primary tumors and is associated with
48 the premature death of patients with different types of metastatic
49 carcinomas, including those from the breast (7), oral mucosa,
50 bladder, pancreas, prostate, colorectum, esophagus, lung, stom-
51 ach, and thyroid glands (8). The elevation of S100A4 can trigger
52 multiple biological functions, including cell migration, invasion,
53 extracellular matrix remodeling, and angiogenesis (8, 9). How-
55ever, it is unknown what are the biologically relevant molecular
56events from the plethora triggered by S100A4 in cultured mam-
57malian cells (10). To generate a genetically tractable experimental
58model to investigate themolecular events triggered by S100A4,we
59have for the ﬁrst time expressed human S100A4 in the fruit ﬂy,
60Drosophila melanogaster by targeting its expression to the develop-
61ing eye lobes (11) and not elsewhere in the brain or CNS (12, 13).
62Drosophila has conserved signal transduction pathways for cell
63cycle, growth control, and cell-to-cell communication (14) and a
64larval phase of only a few days, which can be interrogated
65by inhibitory chemicals applied directly to the growth medium.
66In addition, 70% of human cancer genes are conserved in
67the Drosophila model, but importantly none of the S100 family
68proteins are present (15). Overexpression of oncogenic Ras (Ras-
69
Val12) causes the formation of tumors in the epithelial tissues of
70Drosophila (16), and these can be transformed into a malignant
71phenotype by disruption of suppressor genes such as scribble
72(scrib) and lethal2 (17). In this new model we have for the ﬁrst
73time generated transgenic ﬂies capable of conditionally-expres-
74sing the open-reading frame of humanS100A4 under GAL4/UAS-
75control (18). We show, after multiple crosses, that the S100A4
76gene is required to disseminate RasVal12 tumor cells from the optic
77lobes to the ventral nerve cord (VNC) and further aﬁeld in ﬂy
78larvae. The combination of RasVal12 and loss of scrib in Drosophila
79activates the JNK pathway and this activation induces the matrix
80metalloproteinase MMP1 to allow dissemination of the cancer
81cells in theRasoncogenic system(16). Therefore,wehave assessed
82whether c-Jun and Drosophila MMP1 are downstream targets for
83promoting dissemination in our RasVal12/S100A4 novel larval
84model using ﬂy genetics and inhibitory chemicals, and whether
85there is a uniquely similar association between S100A4 and
86mammalian MMPs in human breast cancer.
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89 Materials and Methods
90 Expression of S100A4 in Drosophila melanogaster
91 HumanS100A4 wild-type (S100A4wt; ref. 19) and inactive
92 mutantS100A4D2 (20) were cloned and expressed in transgenic
93 ﬂies as described in Supplementary Methods. Stable transgenic
94 lines were checked for S100A4 expression by crossing with da-
95 GAL4 ﬂies (18) and Western blotted. Resultant S100A4wt and
96 S100A4D2 progeny produced (mean  SE) similar 7.7  0.6 ng
97 and 8.8  0.7 ng S100A4 protein per 20 ﬂies, respectively,
98 compared with undetectable levels (<0.1 ng) in parental con-
99 trols [Student t test (STT); P ¼ 0.29]. Remaining details are in
100 Supplementary Methods. All initial Drosophila strains were
101 described previously (21), remaining details are in Supplemen-
102 tary Methods. The ﬂies were maintained in standard yeast agar
103 medium at 25C in a 12-hour light–dark incubator (21).
104 Metastatic assay
105 The eyeless-FLP–induced recombination of the FRT-ﬂanked y
106 linker in Act>y>GAL4 results in reconstitution of Actin-GAL4 and
107 expression of UAS-GFP, and other UAS elements, in the devel-
108 oping eye (22). Dissemination of GFP from its original site of eye-
109 antennal discs to VNCs was scored for each genotype/experimen-
110 tal condition on a scale of 0 to 3 (16). GFP localized in the optic
111 lobes scored zero (stage 0), GFP on one side of the VNC scored 1
112 (stage I), on two sides of VNC scored 2 (stage II), and dissemi-
113 nation further into the VNC scored 3 (stage III). Average stage
114 score of metastasis (ASSM) SE was recorded for each genotype/
115 experimental condition. Fluorescent staining is described in Sup-
116 plementaryMethods. Confocal images of GFPwere captured (21)
117 and analyzed using ImageJ software (23), as described in Sup-
118 plementary Methods. Corrected integrated ﬂuorescence intensity
119 (CIFI) ¼ integrated intensity  (area of selected background
120 brain  mean ﬂuorescence density of background) (23). Mean
121 CIFI  SE was recorded.
122 Western blot analysis
123 This is described in Supplementary Methods. To correct for any
124 loading differences, original intensity of each bandwas divided by
125 that of actin. Intensity of each band for a particular larval group
126 was then expressed as a ratio of that in the RasVal12 larvae. Mean
127 value of three experiments SE was recorded. To ensure the
128 intensity of band signals lay within the linear range, a plot of
129 band intensity against mg GAPDH was drawn (y ¼ 43947 
130 42398, r2 ¼ 0.997) and band intensity for any protein outside
131 the linear rangewas excluded from thedata and if necessary the gel
132 was rerun with higher or lower levels of total protein.
133 Drug treatment
134 Inhibitors, JNK-IN-8 (kindly provided by Nathanael S. Gray,
135 HarvardMedical School, Boston,MA; ref. 24) and batimastat (cat.
136 no.: SML0041; Sigma-Aldrich; ref. 25) were added directly from
137 1mg/mL stock dissolved inDMSO to larvalmediumpreheated to
138 55–60C. Same concentration of DMSO was added to controls
139 without inhibitors. The drugs were incubated with the larvae
140 continuously until harvesting at the third instar stage, equivalent
141 to 7 days.
142 Statistical analyses
143 The signiﬁcance of the difference between two categorical
144 groups for each genotype, those with and those without
Figure 1.
A, Fluorescent images of GFP and MMP1 in larval CNS of different male
recombinant Drosophila. CNS was dissected from third instar larvae of
Drosophila with the following backgrounds: RasVal12(RasV12) only; S100A4
wild type (S100A4wt) only; RasVal12, S100A4wild type (RasV12/S100A4wt); and
RasVal12, S100A4D2 (RasV12/S100A4D2). Representative CNS images show
green ﬂuorescence due to endogenous GFP, red ﬂuorescence due to
ﬂuorescently labeled antibodies to matrix metalloproteinase1(MMP1), and
merged ﬂuorescent images are due to GFP and anti-MMP1. The outline of the
relevant structures of the brain including optic lobes (OL) and ventral nerve cord
(VNC) are indicated by the brokenwhite line. The regionwhich clearly expresses
MMP in RasVal12, S100A4 transgenics (arrows), and the same region in RasVal12
transgenics (arrow head) are shown (Scale bar, 100 mm). B, Histogram of
resultant recombinant larvae. The percentage (percent) larvae with different
stages (0–III) ofmetastasis from the optic lobes to the ventral nerve cords (VNC)
is shown for the recombinant Drosophila. The VNC of at least 50, third instar
larvae were scored for the extent of metastasis on a sliding scale (Materials and
Methods): from stage 0 (blue), stage I (red), stage II (green), and stage III
(purple). Larvae containing RasVal12/S100A4 were signiﬁcantly different from
these containing RasVal12 alone, S100A4 alone, and RasVal12/S100A4D2 (Fisher
exact test P < 0.0001) and between larvae containing RasVal12 and RasVal12/
S100A4D2 (P ¼ 0.012 Q5).
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147 metastases was determined by Fisher exact test, recording two-
148 sided values of P. The signiﬁcance of the difference in ASSM, in
149 CIFI for GFP and MMP1, and in mean corrected intensity of each
150 protein band in Western blots were calculated using two-sided
151 Student t test (Stats Direct). Differences considered signiﬁcant
152 when P < 0.05.
153 Patients and specimens
154 A retrospective study was undertaken using samples of 183
155 primary tumors from unselected breast cancer patients, as
156 described previously (26, 27). Ethical approval was obtained
157 from NRES Committee, North West REC.Ref. 12/NW/0778, Pro-
158 tocol no. UoL000889, IRAS no. 107845. Samples were preserved
160in neutral buffered-formalin and embedded in parafﬁn-wax, as
161described previously (7).
162IHC staining
163This is described in Supplementary Methods. Western blots of
164breast cell lines veriﬁed the speciﬁcity of all three mAbs to MMPs
165yielding apparent molecular weights of 73,99,75 kDa for secreted
166latent MMP2, 9, 13, respectively, consistent with those reported
167recently (28). Remainders were veriﬁed previously (27). IHC-
168stained sections were analyzed and scored (7, 26, 28, 29), as
169recorded in Supplementary Methods. Association of staining for
170MMP2, 9, and 13 with patient survival time is reported in
171Supplementary Methods.
Figure 2.
Tumor dissemination in different recombinant Drosophila larvae. A, Average stage of metastatic spread in RasVal12/S100A4 ﬂies. ASSM of the primary tumor in the
optic lobe spreading to the VNC is shown for male recombinant Drosophila with genetic backgrounds of: RasVal12(RasV12), S100A4 wild type only
(S100A4wt), RasVal12plus S100A4 wild type (RasV12/S100A4wt), and RasVal12 plus S100A4mutantD2 (RasV12/S100A4D2). At least 50 larvae were scored
(Materials and Methods) and results are expressed as mean  SE. Both double transgenic ﬂies were signiﬁcantly different from ﬂies with RasVal12genotype
(STT.P  0.005) and RasVal12/S100A4wt from RasVal12/S100A4D2 genotype (P ¼ 0.0001). B, Fluorescence intensity of CNS images of RasVal12/S100A4 ﬂies.
Endogenous ﬂuorescence from GFP (green) and from exogenously-added labeled antibody to MMP1 (red) were recorded. CIFI of images of the dissected CNS from
the same larvae in A were computed as described in "Methods." Mean  SE is shown. For GFP green ﬂuorescence, RasVal12/S100A4wt versus RasVal12only,
S100A4wt only, or RasVal12/S100A4D2 (STT.P < 0.0001); RasVal12 vs. RasVal12/S100A4D2 (P ¼ 0.49). For MMP-1 red ﬂuorescence, RasVal12/S100A4wt versus
RasVal12only, S100A4wt only, and RasVal12/S100A4D2 (STT.P < 0.0001); but RasVal12 versus RasVal12/S100A4D2larval CNS (P ¼ 0.15). C, Average stage of metastatic
spread in male and female JNK-suppressed RasVal12/S100A4 ﬂies. ASSM of the primary tumor in the optic lobe spreading to the VNC is shown for recombinant
Drosophilamale and female larvae with the genetic backgrounds of RasVal12/S100A4wt in which the BskDN dominant suppressor of JNK is expressed only in female
ﬂies. At least 20 larvaewere scored as inA. Results are expressed asmean SE and therewas a highly signiﬁcant difference (STT.P <0.0001).D,Quantiﬁcation of the
levels of ﬂuorescent GFP and b-galactosidase in JNK suppressed ﬂies. Endogenous ﬂuorescence fromGFP (green) and from exogenously-added labeled antibody to
b-galactosidase (b-Gal) (red) were recorded. CIFI of images of the dissected CNS from the same larvae as in C were computed for male and female Drosophilawith
the RasVal12/S100A4wt genetic background. Mean  SE is shown. The b-galactosidase is a marker of the activity of JNK (Materials and Methods). For GFP
green ﬂuorescence and b-galactosidase red ﬂuorescence, signiﬁcant reduction for female versus male RasVal12/S100A4wt larvae (STT.P < 0.0001 and P ¼ 0.004,
respectively).
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174 Results
175 Cooperation of RasVal12 and S100A4 in producingmetastases in
176 recombinant Drosophila
177 The brain containing the CNS was dissected from at least ﬁfty,
178 third instar larvae of different recombinantDrosophila.Male larvae
179 with the genetic background RasVal12 alone (RasVal12 larvae)
180 produced GFP-ﬂuorescent tumors almost exclusively in the eye
181 lobes (Fig. 1A) of 48 of 53 cases, with only 5 of 53 cases extending
182 intooneor theother sideof theVNC(Fig. 1B). Extent ofmetastasis
183 was semiquantiﬁed as described in Materials and Methods to
184 produce an ASSM. There were no GFP-tumor deposits in the eye
185 lobes or elsewhere in S100A4 larvae (Figs. 1A and B and 2A). The
186 RasVal12/S100A4wtrecombinant larvae produced metastasis to the
187 VNC (Fig. 1C) in a signiﬁcantly higher number of 53 of 59 cases
188 [Fisher exact test,P (FET.P)<0.0001; Fig. 1B], increasing theASSM
189 by a signiﬁcant 24-fold overRasVal12larvae [Student t test P (STT.P)
190 < 0.0001; Fig. 2A]. There was also extensive metastasis to other
191 organs, particularly to the gut and gonads (Supplementary Fig.
192 S1). The RasVal12/S100A4D2 inactive mutant larvae (Materials and
193 Methods) produced a signiﬁcantly lower number of 16 of 56with
194 metastasis to the VNC (FET.P < 0.0001; Fig. 1B), with signiﬁcant
195 5.7-fold reduction in ASSM compared to RasVal12larvae (STT.P ¼
196 0.0001; Figs. 1A and 2A). The CIFI of GFP (Materials and Meth-
197 ods) for images taken of the dissected CNS of RasVal12larvae
198 was increased by a signiﬁcant 4.1-fold in RasVal12/S100A4wt
199 larvae (STT.P < 0.0001; Fig. 2B), but there was no signiﬁcant
200 difference in CIFI of RasVal12/S100A4D2mutant larvae compared
201 with RasVal12larvae (STT.P ¼ 0.49; Fig. 2B).
202 Quantiﬁcation of Ras, GFP, and S100A4 levels by Western blot
203 analysis
204 Antibodies to S100A4 detected a speciﬁc band of the correct
205 apparent molecular weight of 9 kDa in all ﬂy lines containing the
206 S100A4wt or S100A4D2mutant gene, but no corresponding band
207 in larvae containing RasVal12 alone (Supplementary Fig. S2).
208 Larvae containing the RasVal12/S100A4wt and RasVal12/S100A4D2
209 genes produced a signiﬁcant increase in Ras and a similar increase
210 in GFP over that in larvae containing RasVal12 alone (STT.P <
211 0.001; Table 1). Protein bands of Ras and GFP were observed at
212 the correct molecular weights (21 and 27 kDa, respectively;
213 Supplementary Fig. S2 and Table 1). There was also highly
215signiﬁcant increases of 220  5- and 85  11-fold in S100A4
216protein in larvae containing the RasVal12/S100A4wt and RasVal12/
217S100A4D2 genes, respectively (P < 0.0001; Table 1), when nor-
218malized to GFP. Thus, there is a signiﬁcant association of expres-
219sion of active S100A4 and metastasis in this model system.
220Increased levels of activated JNK and MMP1 in Ras and
221S100A4-overexpressing larvae
222Levels of JNK in RasVal12 and RasVal12/S100A4wt larvae were not
223signiﬁcantly different in Western blots analysis (STT.P ¼
2240.50; Table 1). However, levels of activated phospho-JNK and
225MMP1 at the reported molecular weights of 46 and 52 kDa,
226respectively (30), rose signiﬁcantly by 13.1  0.6- and 3.8 
2270.1-fold, respectively, when normalized to GFP, in RasVal12/
228S100A4wt compared toRasVal12larvae (P<0.0001; Supplementary
229Fig. S2 and Table 1). Therewas no signiﬁcant increase in phospho-
230JNK, JNK, andMMP1 in RasVal12/S100A4D2 compared to RasVal12-
231larvae. In S100A4wt larvae alone, the levels of phospho-JNK, JNK,
232and MMP1 were signiﬁcantly lower (P < 0.0001, P < 0.0001, P ¼
2330.02; Supplementary Fig. S2 and Table 1), probably reﬂecting the
234absence of any primary tumor (Figs. 1A and B and 2A). There was
235also a modicum of red ﬂuorescence for MMP1 in the eye lobes of
236RasVal12larvae (Fig. 1A and B), which rose signiﬁcantly in RasVal12/
237S100A4wt larvae (P < 0.0001; Fig. 2B) showing extensive staining
238of the VNC (Fig. 1A and B). There was no signiﬁcant difference in
239CIFI for RasVal12 and RasVal12/S100A4D2 larvae (Fig. 2B).
240Activated JNK and MMP are downstream effectors in Ras and
241S100A4-overexpressing larvae
242To determine the requirement for JNK signaling in the meta-
243static phenotypes, we expressed dominant-negative JNK encoded
244by basket (BskDN), together with RasVal12 and S100A4. When
245female and male siblings with and without BskDN, respectively
246(Materials andMethods) were examined, 15/15male, but only 2/
24715 female larvae produced extensivemetastases to theVNC(FET.P
248<0.0001; Supplementary Fig. S3). ASSMandCIFIwere reduced by
249a signiﬁcant 17- and 2.8-fold in female larvae, respectively (STT.P
250< 0.0001; Fig. 2C and D). The expression of a genetically-engi-
251neered marker of JNK activity, puc-LacZ was followed by its
252induction of b-galactosidase (Materials and Methods; Supple-
253mentary Fig. S3). The CIFI for red ﬂuorescent antibody to b-galac-
254tosidase fell signiﬁcantly by 4.7-fold in females (P ¼ 0.004;
Table 1. Quantiﬁcation of Western blotsQ6 of different Drosophila lines
Mean relative abundanceb
Antibody toa RasVal12 S100A4wt RasVal12/S100A4wt RasVal12/S100A4D2
(A) Ras 1  0.05 0.0097  0.001 3.56  0.08c 1.96  0.16c
(B) GFP 1  0.04 0.011  0.002 3.50  0.05c 1.60  0.10c
(C) S100A4 1  0.06 9.62  2.1 742  19d 136  18d
(D) P-JNK 1  0.01 0.19  0.02e 40.5  0.2d 1.32  0.08
(E) Total JNK 1  0.04 0.23  0.01e 1.15  0.07 1.04  0.10
(F) MMP 1  0.04 0.40  0.07f 13.1  0.3 0.498  0.001
MMP 1  0.04 nd 2.17  0.08g nd
Abbreviation: nd, not determined.
aTen mg protein larval extracts were treated with the antibody shown in Western blots of Supplementary Fig. S2.
bMean relative abundance after scanning the blots by densitometry (Materials and Methods) and the area under the peak corresponding to each protein was ﬁrst
normalized to that of actin and then ratioed to the level of that protein in the RasVal12male larvae which was arbitrarily set at 1. Mean relative abundance  SE from
three separate experiments.
cStudent t test P < 0.001 over RasVal12 male larvae.
dStudent t test P < 0.0001 over RasVal12 male larvae or S100A4wt male larvae.
eStudent t test P < 0.0001 over RasVal12 male larvae.
fStudent t test P ¼ 0.02 over RasVal12 male larvae.
gStudent t test P < 0.0001, for female over male larvae.
Ismail et al.
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257 Supplementary Fig. S3 and Fig. 2D). InWestern blots analysis, the
258 level of MMP1 protein normalized to that in male RasVal12larvae
259 fell 6.0-fold from 13.1 0.3 to 2.17 0.08 inmale versus female
260 larvae (P < 0.0001; Table 1).
261 When increasing concentrations of the JNK-IN-8 inhibitor (24)
262 were added to male RasVal12/S100A4wt larvae, there was a signif-
263 icant fall in ASSM of 2.5-fold for 1 mmol/L (STT.P < 0.0001), but
264 thereafter a more gradual stepwise decline; the overall fall being
265 5.8-fold (P < 0.0001; Supplementary Fig. S4A and S4B; Fig. 3A).
266 There was a similar signiﬁcant decline in CIFI for GFP of 2.7-fold
267 (P¼ 0.002) for 1 mmol/L inhibitor and then successive signiﬁcant
268 decreases; the overall fall being 11.4-fold (P < 0.0001) (Fig. 3A).
269 There was also a similar signiﬁcant decline in CIFI for antibodies
270 to endogenous MMP1 upon addition of 1 mmol/L JNK-IN-8
271 (Supplementary Fig. S4A and S4B; P ¼ 0.0005), then further
272 successive signiﬁcant decreases; the overall fall being 8.3-fold
273 (P < 0.0001; Fig. 3AQ7 ).
274 When increasing concentrations of the inhibitor of MMP activ-
275 ity, Batimastat (25) was added to RasVal12/S100A4wt larvae, there
276 were signiﬁcant falls in ASSM of 3.4-fold for 5 mmol/L (P <
277 0.0001), but thereafter the decline was more gradual; the overall
278 fall being 16.4-fold (P < 0.0001; Supplementary Fig. S4C and
279 S4D; Fig. 3B). There was a similar signiﬁcant decline in CIFI for
280 GFP of 3.5-fold (P ¼ 0.0002) for 5 mmol/L inhibitor and then
281 successive nonsigniﬁcant decreases. The overall fall was 8.4-fold
282 (P < 0.0001; Fig. 3B). There was also a rapid signiﬁcant decline
283 in CIFI for antibodies to endogenous MMP1 upon addition of
284 5 mmol/L batimastat (Supplementary Fig. S4C and S4D) of 5.2-
285 fold (P ¼ 0.028), then nonsigniﬁcant successive falls; the overall
286 fall being 10.3-fold (P < 0.0001; Fig. 3B). Thus, a deﬁnite pathway
287 has been established between S100A4 andMMP1 for induction of
288 metastasis in this model system.
289 AssociationofMMPswithpatient survival time inhumanbreast
290 cancer
291 Next, we investigated the relationship in human breast cancer
292 between the more commonly-occurring, mammalian MMPs,
293 MMP2, 9, 13, and patient demise as a result of metastatic cancer
294 (31). On examination of 183 breast carcinomas for IHC for these
295 three MMPs, 32% to 67% contained carcinoma cells which were
296 negatively stained (<1% carcinoma cells stained), 19% to 26%
297 were borderline stained (1–5% carcinoma cells stained), and the
298 rest (15–47%) were stained to varying degrees (Fig. 4 and Sup-
299 plementary Fig. S5; Supplementary Table S1). There were also
300 some reactive stromal cells,mainlymyoﬁbroblasts,macrophages,
301 and neutrophils which stained (Fig. 4). Assessment of staining
302 class was made only for the malignant cells. Staining for individ-
303 ual MMPs was abolished by prior incubation of each antibody
304 with the requisite MMP (Supplementary Fig. S5).
305 To determine whether there was any association between
306 staining for the separate MMPs and of survival of patients,
307 Kaplan–Meier survival curves were plotted for different staining
308 groups. Overall, there was a signiﬁcant difference in staining for
309 each MMP (Wilcoxon Gehan Statistics, P < 0.001). However, the
310 largest signiﬁcant differences occurred between the () and (þ)
311 staining groups for MMP2, 9, and 13, respectively (Supplemen-
312 tary Table S2). The 183 patients were therefore separated into two
313 categorical groups using a cutoff of 5% stained carcinoma cells for
314 each MMP. Only 11  4% survived with positively stained
315 tumors, compared to 81  4% with negatively stained tumors
316 for MMP2; 10 6% vs. 58 4% for MMP9; and 22 5% versus
31875  5% for MMP13 (Fig. 5). All differences were highly signif-
319icant (P < 0.001) with median duration of survival of 47, 32, and
32052 months for MMP2, 9, and 13 positively stained tumors versus
321228 months in all cases of negatively stained tumors. These
322corresponded to relative risks (RR) of death of 9.04 (95% CI,
3235.32–15.36), 4.69 (95%CI, 2.89–7.62), and 4.87 (95%CI, 2.98–
3247.97), respectively. Results for S100A4 with a cutoff of 5% were
325similar to that for individual MMPs with only 9  4% surviving
326versus 80 4% for unstained tumors, median survival time of 46
327months versus 228 months (x2 ¼ 71.8, P < 0.001), and RR of
328patient death of 9.96 (95% CI, 5.87–16.9; Supplementary Table
329S3). Patients with tumors stained positively for all three MMPs
330showed no signiﬁcant increase in mortality (7%  6%), decrease
Figure 3.
Tumor dissemination in recombinant ﬂies treated with either JNK-IN-8 (A) or
Batimastat (B). Drosophila larvae with genetic background of RasVal12/
S100A4wtwere fed either (A) 0, 1, 5, or 10 mmol/L of the JNK inhibitor JNK-IN-8
or (B) 0, 5, 10, or 25 mmol/L of the MMP1 inhibitor Batimastat in their medium
(Materials and Methods). At least 20 larvae were scored and ASSM was
computed as described in Materials and Methods. These same larvae were
dissected, stained, and scored for endogenous green ﬂuorescence fromGFP and
for red ﬂuorescence from exogenously–added labeled antibody to MMP1.
The CIFI was computed as described in Materials and Methods. Results are
shown asmean SE. For ASSM, transgenic larvae fed 0mmol/L of inhibitor were
signiﬁcantly higher than for larvae fed 1, 5, and 10 mmol/L JNK-IN-8 or for larvae
fed 5, 10, and 25 mmol/L batimastat (STT.P 0.0001). For JNK inhibitor-treated
larvae, decrease in CIFI for those fed 1, 5, and 10 mmol/L JNK-IN-8 of 2.7, 4.6,
and 11.4 folds, respectively for GFP ﬂuorescence (STT.P 0.002) and of 3.4, 5.1,
and 8.3 folds, respectively, for MMP1-related ﬂuorescence (STT.P0.0005). For
MMP1 inhibitor-treated larvae, decrease in CIFI for those fed on 5, 10, and
25 mmol/L batimastat of 3.5, 4.8, and 8.4 folds, respectively, for GFP
ﬂuorescence (STT.P  0.0002), and of 5.2, 5.9, and 10.3 folds, respectively, for
MMP1-related ﬂuorescence (STT.P ¼ 0.02, 0.07, and 0.06, respectively).
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333 inmedian survival time (30months), or increase inRR (4.96; 95%
334 CI, 2.99–8.24) than staining for eitherMMP2orMMP9 separately
335 (Supplementary Table S2).When all threeMMPswere included in
336 Cox's multivariate regression analysis (Materials and Methods),
337 the individual contributions made to the time of patient demise
338 showed that staining for MMP2 (P < 0.001) and that for MMP9
339 (P¼ 0.025)were independently signiﬁcant while that forMMP13
340 was not (Supplementary Table S3).
341 Association of MMPs with S100A4 and patient survival
342 Results for IHC staining for the 3MMPs using a 5% cutoff were
343 cross-tabulated against pathologic variables and IHC staining for
344 S100A4, S100P (29), estrogen receptor a (ERa), progesterone
345 receptor (PgR), c-erbB-2 (Her2), cytokeratin 5/6 (CK5/6), and
346 CK14 (32). All these variables have been reported to inﬂuence
347 survival times in the same set of patients (26). Positive staining for
348 each of MMP2, 9, and 13 was associated strongly with positive
349 staining for S100A4 when using a 5% cutoff for S100A4. This
350 association was slightly reduced with staining for S100P using a
351 5% cutoff (Table 2). Signiﬁcance of association was much more
352 marked for staining for S100A4 than for S100P when using a 1%
353 cutoff. There was also a signiﬁcant association with staining for
354 CK5/6 and usually for CK14 (Table 2). Positive staining for any
355 MMPwas not signiﬁcantly associatedwith involved lymphnodes,
356 high tumor grade, large tumor size, nor with positive staining for
357 ERa, PgR, or c-erbB-2 (Table 2). There was also a highly signiﬁcant
358 association of staining for each pair of MMPs (Table 2 and
359 Supplementary Table S4).
361When staining for S100A4was tested for its relative probability
362of association (RA) with that for the three MMPs using binary
363logistic regression, that with MMP2 was strongest at 4.21 (P <
3640.001), that withMMP9 of 2.41 was not signiﬁcant, and that with
365MMP13 of 2.17 (P ¼ 0.051) was very nearly signiﬁcant. When
366staining for each of the MMPs, in turn, was assessed with staining
367for S100A4, CK14, ERa, PgR, and c-erb-2, only that for S100A4
368and partially that for CK14 proved to be signiﬁcant (Supplemen-
369tary Table S5). When repeated using a different cutoff for S100A4
370(1% instead of 5%; Table 2) and additionally including that for
371S100P, staining for MMP2 was most closely associated with that
372for S100A4 (Supplementary Table S5). To determine whether the
373three MMPs were independent of S100A4 when related to patient
374survival, they were included in a series of Cox's multivariate
375regression analyses (Materials and Methods; Supplementary
376Table S3). When a single MMP and S100A4 were only included,
377staining for S100A4 always emerged as the most signiﬁcant
378association with patient survival time. Similar results were
379obtained if staining for S100A4 and all threeMMPswere included
380in the same analysis, S100A4 emerged as the most signiﬁcant
381association followed byMMP2 and thenMMP9,whereas that due
382to MMP13 was not signiﬁcant (Supplementary Table S3).
383To determine whether there was coexpression of theMMPs and
384S100proteins, twobreast carcinomaswere chosen thatwere either
385moderately or strongly stained for MMP2, and these were IHC
386restained for S100A4/P, 3 MMPs, CK5/6, and CK14. Exactly the
387same areas were examined for each antigen. The percentage of
388stained cells for S100A4 was not signiﬁcantly different from that
389for MMP2 and MMP13, while staining for S100P was not signif-
390icantly different from that for MMP9 (Supplementary Fig. S6; and
391Supplementary Table S6). Staining for S100A4 orMMP2was also
392not signiﬁcantly different from that for CK5/6, but only in the
393MMP2 moderately-stained carcinomas; all the other paired com-
394binations were signiﬁcantly different (Supplementary Fig. S6; and
395Supplementary Table S6). When serial sections from three breast
396carcinomas strongly-staining forMMP2were doubly IHC-stained
397for S100A4with red and forMMP2with brown chromophores on
398the same section, there were (mean  SE) 80.2  2.2% doubly
399stained cells, 6.9%  0.9% cells stained red for S100A4, 2.9% 
4000.4% cells stained brown for MMP2 and 9.1%  1.5% unstained
401cells (ANOVA, F¼ 669.3, 3 df, P < 0.001; Supplementary Fig. S7).
402Thus, S100A4 is associated with and partially confounded for
403patient survival by the three MMPs to varying degrees.
404Discussion
405We have shown for the ﬁrst time that S100A4 can induce
406metastasis in theDrosophilamodel and that the oncogene RasVal12
407largely fails in this respect. The increase in number of larvae
408bearing VNC metastases (10-fold), in ASSM (24-fold), and in
409CIFI (4.1-fold) for RasVal12/S100A4 over RasVal12 larvae demon-
410strates clearly that S100A4 promotes extensive dissemination
411to the VNC, as well as elsewhere in the larvae (Supplementary
412Fig. S1). The reason for the differences in fold increases is due to
413the method of measurement, the CIFI included GFP ﬂuorescence
414due to the primary as well as the metastases, whereas the ﬁrst
415two parameters relate only to the metastases. That larvae contain-
416ing RasVal12 and inactive S100A4D2 genes (20) show signiﬁcantly
417less metastases (Fig. 1A, 2A, and B), demonstrates that the
418migratory/invasive ability of S100A4 (20) is required for its
419metastatic ability. That S100A4 larvae produce no tumors at all
Figure 4.
Immunohistochemical staining of different breast carcinomas with antibody to
MMP2 (A), MMP9 (B), or MMP13 (C) showing strong brown staining of the
carcinoma cells' cytoplasm. Incubation with antibody to S100A4 (D) or S100P
(E) showing strong, bead-like, cytoplasmic staining. F, Incubationwith antibody
to MMP2 with brown chromophore and to S100A4 with red chromophore
showing most carcinoma cells were stained by both antibodies. Tumors were
selected to show strong staining inA toC for their respectiveMMP, but the same
tumor was stained in D to F as in A (180; scale bar, 20 mm).
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Figure 5.
Association of immunohistochemical staining for MMPs with overall
time of patient survival. Cumulative proportion of surviving patients
as a fraction of the total for each year after presentation for patients
with carcinomas classiﬁed as negatively-stained (set a solid line) or
positively-stained (set b, dotted line) is shown for MMP2 (A), MMP9
(B), and MMP13 (C). Numbers of patients entering each year are
shown below. The two curves are highly signiﬁcantly different in each
case (Wilcoxon statistic x2 ¼ 71.81, 32.50, or 41.90 for A, B, or C,
respectively, 1 df, P < 0.001). Further details are shown in
Supplementary Materials.
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422 (Fig. 1A, 2A, and B) demonstrates that S100A4 alone is non-
423 oncogenic, consistent with previous results in our S100A4 trans-
424 genicmice (33). The increases in Ras andGFPproteins of 3.5- to 4-
425 fold (Table 1) are consistent with the increase in GFP ﬂuorescence
426 of about 4-fold (Fig. 2B) and probably represent the increase in
427 overall tumor mass between the RasVal12 and the RasVal12/S100A4
428 larvae.
429 In agreement with different genetically manipulated Ras onco-
430 genic systems in Drosophila (16, 18), the levels of endogenous
431 activated phospho-JNK and MMP1 rise signiﬁcantly in RasVal12/
432 S100A4 comparedwithRasVal12larvae (Table 1). The rise inMMP1
433 protein is of the sameorder as the increase inﬂuorescently-labeled
434 antibodies toMMP1. That JNK is indeed a downstream effector of
435 RasVal12/S100A4 for metastasis is demonstrated by the reduction
436 in the number with metastases and their ASSM in female BskDN-
437 expressing larvae compared to themale unsuppressed larvae (Fig.
438 2C). That these suppressed values for RasVal12/S100A4 are not
439 signiﬁcantly different from those of the RasVal12 larvae (Fig. 2C)
440 suggests that the predominant driver of the JNK–link tometastasis
441 is the overexpression of S100A4. The 4.7-fold fall in the immuno-
442 ﬂuorescently-detectable b-galactosidase in the female, suppressed
443 RasVal12/S100A4 larvae demonstrates that JNK needs to be acti-
444 vated to stimulatemetastasis. Because of the level of JNKprotein is
445 relatively constant between RasVal12 and RasVal12/S100A4 larvae
446 (Table 1), S100A4 probably triggers activation of JNK by stimu-
447 lating its increase in phosphorylation (24). Results using 10
448 mmol/L JNK-IN-8 conﬁrm that JNK-induced phosphorylation
449 of c-Jun is a necessary step in the S100A4–triggered pathway for
450 metastasis. That there is a fall in CIFI for immunoﬂuorescently
451 detectable MMP1 (Fig. 3B) positions JNK before MMP in any
452 pathway (16). Moreover, the fact that the MMP1 inhibitor,
453 batimastat (25) inhibits ASSM and CIFI for GFP in the RasVal12/
454 S100A4 larvae places MMP1 on the direct pathway to metastasis.
455 The order of this novel S100A4-induced metastatic pathway
456 is: S100A4!phospho-JNK!c-Jun!MMP1!metastasis. Thus,
457 S100A4 appears to replicate the loss of function of suppressor
458 genes scrib and lethal2 (17) or Her2 activation in the JNK/MMP
459 pathway (16, 18). In transgenic mice or chemically transformed
460 rat mammary cells, S100A4 combines with oncogenicNeu (Her2;
462ref. 6) or Ras (4), respectively to stimulate, via the cytoskeleton,
463cell migration, and then subsequent events for invasion/metas-
464tasis (34). However, the involvement of this novel pathway has
465hitherto been unreported.
466The relevance of our unique Drosophila model for S100A4 has
467been pursued in human breast cancer. IHC staining of our cohort
468of 183 breast carcinomas for the individual MMPs2, 9, 13
469demonstrates 15% to 47% primary tumors are stained positively
470using a cut-off of 5%, in approximate agreement with previous
471reports (35, 36). Here we show that the overall duration of
472survival of patients with positively-stained carcinomas is highly
473signiﬁcantlyworse than for those patients classiﬁed asnot staining
474for one of MMP2, 9, or 13 (Fig. 5), in agreement with results
475for MMP2 in hepatocarcinoma (37), skin melanoma (38) and
476for MMP13 in breast (36) and colon cancer (39). In contrast,
477MMP9 has been reported to be a favorable indicator in lymph-
478node-negative breast cancer (40). This favorable prognosis may
479depend on the much higher cutoff employed, because of our
480node-negative group showed no signiﬁcant difference (Wilcoxon
481x2¼ 2.63, 1 df, P¼ 0.11). This difference was signiﬁcantly greater
482forMMP9 staining in our node-positive patients (x2¼18.40, 1 df,
483P < 0.001). The other two MMPs showed similar signiﬁcant
484differences in node-negative and node-positive patients (MMP2
485x2 ¼ 25.46 and 25.39; MMP13 x2 ¼ 14.91 and 12.93, respec-
486tively). These results may suggest that MMP9 operates later than
487the other two MMPs at a post lymph-node-spreading stage in the
488disease process.
489Overall, the RR of patient death in separate univariate analyses
490is greatest for patients with tumors stained for S100A4 (9.96),
491followed closely by those stained for MMP2 (9.04), then for
492MMP13 (4.87), andﬁnally forMMP9(4.69; Supplementary Table
493S3). However, the antibodies used here to detect theMMPs do not
494discriminate between inactive precursors or cleaved active MMPs
495and do not detect inhibitory TIMPs (41). Usually in cultured cells,
496S100A4 increases expression of MMP precursors and this results
497in an enhanced proteolytic activity and cell invasion/metastasis
498(42, 43). Moreover, S100A4 can act both intracellularly (43, 44)
499and extracellularly via RAGE receptors (45, 46) to stimulate MMP
500production. The fact that BskDN inhibits S100A4-induced MMP1
Table 2. Association of IHC staining for MMPs with other tumor variables
Statistical signiﬁcancec
Tumor variablea Patientb no. MMP2 MMP9 MMP13
Lymph nodes 139 0.271 0.564 0.681
Grade 164 0.997 0.656 0.156
Tumor size 177 0.467 0.937 0.985
MMP2 183 — 9.0  107 1.7  1012
MMP9 183 9.0  107 — 1.2  107
MMP13 183 1.7  1012 1.2  107 —
S100A4 (5%) 183 6.6  109 2.9  104 2.4  106
S100A4 (1%) 183 0d 1.2  107 1.9  108
S100P (5%) 163 2.3  107 2.2  103 1.3  107
S100P (1%) 163 1.6  104 0.012 2.4  105
CK14 172 5.7  107 2.8  103 0.372
CK5/6 173 1.6  106 0.035 5.6  103
ERa 181 1.00 1.0 1.0
PgR 172 0.995 0.983 0.549
C-erbB-2 183 0.660 1.00 0.809
aLymphnodeswith orwithout tumor deposits; grade, histologic grades I and II vs. grade III; tumor size<5cmvs.>5cm indiameter; presenceor absence of IHC staining
for molecular variables using 5% cutoff for MMP2, MMP9, MMP13, S100A4 (5%), S100P (5%), ERa, PgR, c-erbB-2, and using a 1% cutoff for S100A4 (1%), S100P (1%),
CK14, and CK5/6.
bNumber of patients from original 183.
cProbability P from Fisher exact test using the Holm–Bonferroni correction calculated as 1  (1  P)n, where n ¼ 12 (Materials and Methods).
dUncorrected P ¼ 7.7  1018.
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503 andmetastasis to theVNC inourDrosophilamodel (Fig. 2C andD)
504 suggests that MMP1 is produced by the tumor cells and not by
505 reactive stromal cells (47), consistent with immunohistochemical
506 results in our human breast cancers. In contrast to the Drosophila
507 model, the three JNK proteins in human cancers can exert both
508 pro- and anti-oncogenic effects depending on the cell type and
509 cross-talk with other kinases (48, 49). Thus, the oncogenic effect
510 of activated JNK cannot be determined in human cancers from the
511 measurement of its level alone, andhencewas not attemptedhere.
512 Upon manipulation in cultured cells, S100A4 has been
513 reported to control production of a single MMP, one of MMP2,
514 9, or 13, depending on the source and sometimes the report (42–
515 45). In contrast, we show here that positive staining for each
516 MMP2, 9, or 13 is separately and in combination very strongly
517 associated with S100A4 and to a lesser extent with S100P (Table
518 2). The signiﬁcant association of staining for MMP2, 9 with the
519 basal cell markers CK5/6, CK14 has been reported previously
520 (50), predominantly placing these MMPs, together with S100A4
521 and S100P, in the most aggressive subtype of breast cancers (26).
522 When tested for RA of staining for S100A4 with the other three
523 MMPs together, S100A4 is more likely to occur with MMP2, and
524 the higher signiﬁcant RAofMMP2 for S100A4over a combination
525 of other proteins conﬁrms this result (Supplementary Table S6).
526 Thus, S100A4 ismore associatedwithMMP2, 13, andS100Pmore
527 withMMP9, at least at the cellular level (Supplementary Table S6).
528 This differential association in the tumor raises the novel possi-
529 bility of synergistic interactions between the S100 proteins (29)
530 occurring via different target MMPs.
531 Multiple longitudinal comparisons with survival time for all
532 three MMPs together in multivariate analysis shows that only
533 MMP2 and MMP9 are independently signiﬁcant, whereas the
534 contribution of MMP13 is confounded by that due to the other
535 twoMMPs (Supplementary Table S3). These results suggest partial
536 overlap occurs between MMP2/MMP9-related pathways and
537 MMP13-related pathways, whereas those related to MMP2 and
538 MMP9 are more separate. This result is consistent with their
539 function, MMP13 is a collagenase which is required to cut col-
540 lagen ﬁbrils ﬁrst, before the two gelatinases, MMP2 orMMP9, can
541 digest the remainder (51).WhenS100A4and eachMMPare tested
542 in combination, the order of reduction in RR for S100A4 isMMP2
543 (42% reduction), then MMP13 (27% reduction) and ﬁnally
544 MMP9 (11% reduction), whereas the reduction in RR for each
545 MMP separately with S100A4 is similar (44%, 40%, and 43%,
547respectively; Supplementary Table S3). These results suggest the
548pathways that S100A4 may trigger leading to premature death
549from metastatic disease overlap, to some extent, with those
550triggered by the three MMPs, the most overlap being with
551MMP2-related and then with MMP13-related pathways. The
552results for the close association of S100A4 and MMP2 are con-
553ﬁrmed at the level of the cell where 91% of S100A4-containing
554cells also contain MMP2 and 96% of MMP2-containing cells also
555contain S100A4 (Supplementary Fig. S7). The considerable
556enhancing effect of S100P on S100A4-linked patient demise
557(29) may then be attributable, at least in part, to S100P targeting
558different MMPs from those targeted by S100A4 (Supplementary
559Table S6). This differential targeting ofMMPsby S100proteins is a
560novel mechanism for generation of the known synergy between
561different MIPs in the development of many cancers.
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